Full-Time

Quality Assurance Engineer

Confirmed live in the last 24 hours

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

No salary listed

Senior

Hyderabad, Telangana, India

Category
QA & Testing
Automation Testing
Manual Testing
Quality Assurance
Required Skills
JIRA
Selenium
Requirements
  • Master’s degree with a minimum of 3 years of Information Systems experience OR
  • Bachelor’s degree with a minimum of 5 years of Information Systems experience
Responsibilities
  • Collaborate with Product Owners and developers to understand requirements and acceptance criteria.
  • Participate in backlog refinement and sprint planning to ensure testable user stories.
  • Develop comprehensive test plans and strategies for web applications.
  • Design and create detailed, comprehensive, and well-structured test cases.
  • Identify test requirements and prepare test data.
  • Perform manual testing of web applications, including functional, integration, regression, and exploratory testing.
  • Develop and maintain automated test scripts for web applications using tools like Selenium, Cypress, or similar.
  • Ensure automated tests are run regularly and results are reported and analyzed.
  • Conduct performance and load testing to ensure web applications can handle expected user loads.
  • Identify, document, and track bugs using a bug tracking system like JIRA or similar.
  • Work closely with developers to reproduce issues and verify fixes.
  • Stay up to date with industry trends and advancements in testing methodologies and tools.
  • Continuously improve the QA processes and tools used by the team.
Desired Qualifications
  • Experience in modern web application testing and automation
  • Experience of DevOps, Continuous Integration and Continuous Delivery methodology
  • Experience with issue-tracking and agile project management systems like JIRA
  • Has experience in testing Rest web services
  • Able to communicate technical or complex subject matters in business terms
  • Jira Align experience
  • Miro experience
  • Relevant to job responsibilities any certification - preferred
  • Excellent analytical and gap/fit assessment skills
  • Sees opportunities for innovation and offers new insights. Takes the initiative to experiment with new software frameworks
  • Strong verbal and written communication skills
  • Ability to work effectively with global, virtual teams
  • High degree of initiative and self-motivation
  • Team-oriented, with a focus on achieving team goals
  • Strong presentation and public speaking skills

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are derived from living organisms, to address conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a large portion of its earnings to discover new therapies. The goal of Amgen is to improve patient care and outcomes by providing effective therapeutic solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen's investment in AI aligns with trends in biotechnology innovation.
  • Institutional investments indicate strong market confidence in Amgen's growth.
  • FTC clearance of the Horizon merger may ease future regulatory hurdles.

What critics are saying

  • Competitors' AI-driven drug discovery could outpace Amgen's traditional R&D methods.
  • FTC scrutiny of mergers may complicate Amgen's future growth strategy.
  • Advancements in quantum technologies could pose a competitive threat to Amgen.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline of potential new therapies in development.
  • Amgen's acquisition of Horizon Therapeutics enhances its rare disease portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.

BioSpace
Sep 19th, 2023
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans

The consent agreement struck between the FTC and Amgen and Horizon Therapeutics could have significant implications for ongoing and future M&A challenges, experts told BioSpace.